FLT3 inhibitors in acute myeloid leukemia

FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved ...

Source: Journal of Hematology and Oncology - December 4, 2018 Category: Hematology Authors: Mei Wu, Chuntuan Li and Xiongpeng Zhu Tags: Review Source Type: research